In the current study, the deletion of Shp2-inhibited Erk phosphorylation and theIL-6-induced enhancement of cell migration and invasion, indicates that Shp2 may also act as a positive regulator in IL-6-signaling-mediated cancer progression. Here, IL6 is linked to cancer.